

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6855)

Voluntary Announcement

APG-115 completed dosing of the first patient in Phase Ib clinical study in China

Ascentage Pharma Group International (the “**Company**” or “**Ascentage Pharma**”) is pleased to announce that the Company’s novel MDM2-p53 inhibitor candidate, APG-115 has completed dosing of the first patient in its Phase Ib clinical study in China. This is the first clinical study of APG-115 in Chinese patients with hematologic malignancies.

This multicenter Phase Ib clinical study in China is designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of APG-115 as a single agent and in combination with azacytidine or cytarabine in treating patients with hematologic malignancies, including relapsed/refractory acute myeloid leukemia and relapsed/progressed high/very high risk myelodysplastic syndrome.

APG-115 is an orally administered, selective, small-molecule inhibitor of the MDM2-p53 protein-protein interaction (PPI). APG-115 is the first MDM2-p53 inhibitor entering clinical stage in China, with multiple ongoing clinical studies in treating solid tumors in China and the United States. At present, APG-115 is simultaneously advancing its clinical development in a range of hematologic malignancies globally.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: We cannot guarantee that we will be able to obtain further approval for, or ultimately market APG-115 successfully.

By order of the Board
Ascentage Pharma Group International
Dr. Yang Dajun
Chairman and Executive Director

Suzhou, People's Republic of China, July 22, 2020

As at the date of this announcement, the board of directors of the Company comprises Dr. Yang Dajun as chairman and executive director, Dr. Wang Shaomeng, Dr. Tian Yuan, Mr. Zhao Qun, Dr. Lu Simon Dazhong and Mr. Liu Qian as non-executive directors, and Mr. Ye Changqing, Dr. Yin Zheng and Mr. Ren Wei as independent non-executive directors.